Arsenic resistance protein 2 and microRNA biogenesis: Biological implications in cancer development

Pharmacol Ther. 2023 Apr:244:108386. doi: 10.1016/j.pharmthera.2023.108386. Epub 2023 Mar 16.

Abstract

Arsenic resistance protein 2 (Ars2) is a nuclear protein that plays a critical role in the regulation of microRNA (miRNA) biogenesis. Ars2 is required for cell proliferation and for the early stages of mammalian development through a possible effect on miRNA processing. Increasing evidence reveal that Ars2 is highly expressed in proliferating cancer cells, suggesting that Ars2 may be a potential therapeutic target for cancer. Therefore, development of the novel Ars2 inhibitors could represent the novel therapeutic strategies for treatment of cancer. In this review, we briefly discuss the mechanisms by which Ars2 regulates miRNA biogenesis and its impact on cell proliferation and cancer development. Particularly, we mainly discuss the role of Ars2 in the regulation of cancer development and highlight pharmacological targeting of Ars2 as a promising cancer therapeutic strategy.

Keywords: Arsenic resistance protein 2; Cell proliferation; RNA-induced silencing complex; The nuclear cap-binding complex; cancer; miRNA biogenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arsenic*
  • Cell Proliferation
  • Humans
  • Mammals / genetics
  • Mammals / metabolism
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Nuclear Proteins / genetics

Substances

  • MicroRNAs
  • Arsenic
  • Nuclear Proteins